Physician profile
John M Patterson
NPI 1063419794
$739.30
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $45.24 · 2021: $23.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $123.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $101.72 | 2019 | |
| Novo Nordisk INC | $62.10 | 2019 | |
| Ferring Pharmaceuticals INC. | $55.14 | 2019 | |
| Abbvie INC. | $49.24 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $37.09 | 2019 | |
| Boston Scientific Corporation | $29.55 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Integra Lifesciences Corporation | $18.31 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.54 | 2020 | |
| Janssen Biotech, INC. | $15.94 | 2019 | |
| Olympus America INC. | $15.80 | 2019 | |
| Blue Earth Diagnostics | $15.78 | 2019 | |
| Antares Pharma, INC. | $14.90 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $14.88 | 2019 | |
| Coloplast Corp | $14.71 | 2019 | |
| 180 Medical, INC. | $13.46 | 2019 | |
| Allergan, INC. | $12.54 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.